|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-9-23
|
|
pubmed:abstractText |
New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC). They have resulted in better survival compared with megestrol acetate (MEG) in a number of studies. The authors performed a pooled analysis including all the Phase III trials published between 1996 and 2004 evaluating the AIs approved or not by the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medical Products (EMEA) as second-line endocrine therapy (ET) for patients with MBC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:BriaEmilioE,
pubmed-author:CarliniPaoloP,
pubmed-author:CognettiFrancescoF,
pubmed-author:Di CosimoSerenaS,
pubmed-author:FabiAlessandraA,
pubmed-author:FeliciAlessandraA,
pubmed-author:FerrettiGianluigiG,
pubmed-author:GiannarelliDianaD,
pubmed-author:MilellaMicheleM,
pubmed-author:MottoleseMarcellaM,
pubmed-author:NisticòCeciliaC,
pubmed-author:PapaldoPaolaP,
pubmed-author:RuggeriEnzo MariaEM,
pubmed-author:TerzoliEdmondoE
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1335-42
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16088965-Aged,
pubmed-meshheading:16088965-Androstenedione,
pubmed-meshheading:16088965-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16088965-Aromatase Inhibitors,
pubmed-meshheading:16088965-Breast Neoplasms,
pubmed-meshheading:16088965-Carcinoma,
pubmed-meshheading:16088965-Clinical Trials, Phase III as Topic,
pubmed-meshheading:16088965-Confidence Intervals,
pubmed-meshheading:16088965-Dose-Response Relationship, Drug,
pubmed-meshheading:16088965-Drug Administration Schedule,
pubmed-meshheading:16088965-Fadrozole,
pubmed-meshheading:16088965-Female,
pubmed-meshheading:16088965-Humans,
pubmed-meshheading:16088965-Middle Aged,
pubmed-meshheading:16088965-Neoplasm Staging,
pubmed-meshheading:16088965-Neoplasms, Hormone-Dependent,
pubmed-meshheading:16088965-Nitriles,
pubmed-meshheading:16088965-Postmenopause,
pubmed-meshheading:16088965-Probability,
pubmed-meshheading:16088965-Prognosis,
pubmed-meshheading:16088965-Remission Induction,
pubmed-meshheading:16088965-Risk Assessment,
pubmed-meshheading:16088965-Survival Analysis,
pubmed-meshheading:16088965-Triazoles
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
|
|
pubmed:affiliation |
Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy. pcarlini@iol.it pcarlini@yahoo.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review,
Research Support, Non-U.S. Gov't
|
